Corteva Q2 Earnings Preview: What You Need to Know

Corteva is expected to report Q2 earnings of $1.89 per share, up 3.3% YoY, and a fiscal 2025 EPS of $3.01, up 17.1% YoY. The company's stock has surged 34.7% over the past 52 weeks, outperforming the S&P 500 Index. Corteva's Q1 results saw a 1.7% YoY drop in topline revenue, but a 27% YoY increase in non-GAAP EPS. The stock maintains a "Strong Buy" rating with a mean price target of $77.65, representing a 6.4% upside from current price levels.

Corteva Inc. (NYSE: CTVA) has reported its Q1 results, showcasing a 1.7% year-over-year (YoY) drop in topline revenue, but a significant 27% YoY increase in non-GAAP earnings per share (EPS). The company is expected to report Q2 earnings of $1.89 per share, up 3.3% YoY, and a fiscal 2025 EPS of $3.01, up 17.1% YoY. The stock has surged 34.7% over the past 52 weeks, outperforming the S&P 500 Index [3].

Analysts have remained optimistic about Corteva's prospects. RBC Capital recently raised its price target on Corteva to $85 from $74, reaffirming an Outperform rating. The firm noted that the company's long-term earnings trajectory and strategic execution are driving confidence [1]. RBC's updated forecast reflects modest upward revisions to EBITDA estimates for fiscal 2025 and 2026, with projections now at $3.78 billion and $4.1 billion, respectively [1].

Several tailwinds are expected to support Corteva's performance. These include a recovery in Brazilian seed plantings, reduced currency headwinds, and potential share gains from farmers switching away from Dicamba herbicides. Additionally, improving margins from cost discipline, operational efficiencies, and lower royalty payments are likely to enhance the earnings outlook [1].

Corteva's stock has faced a losing streak, with cumulative losses of -6.4% over the past seven days, but the company remains well-positioned to outperform. The stock maintains a "Strong Buy" rating with a mean price target of $77.65, representing a 6.4% upside from current price levels [3].

In other recent news, BMO Capital has raised its price target for Corteva to $86, citing the company's strong growth profile and projecting 2026 EBITDA at $4.1 billion. Jefferies also reiterated a Buy rating on Corteva, increasing its price target to $92, highlighting the company's growth potential and its strategic initiatives in technology and policy changes [4].

However, Corteva is also facing regulatory scrutiny. Turkey's antitrust regulator has initiated an investigation into several companies in the seed market, including Corteva Turkey, over allegations of territory sharing and exchanging competition-sensitive information [4].

References:
[1] https://site.financialmodelingprep.com/market-news/fmp-rbc-lifts-corteva-price-target-keeps-outperform-rating
[2] https://www.gurufocus.com/news/2972152/central-garden-pet-raises-fiscal-2025-nongaap-eps-outlook-fiscal-2025-nongaap-eps-now-expected-to-be-approximately-260-centa-stock-news
[3] https://www.trefis.com/articles/569572/ctva-stock-down-6-4-after-7-day-loss-streak/2025-07-16
[4] https://za.investing.com/news/analyst-ratings/corteva-stock-price-target-raised-to-85-from-74-at-rbc-capital-93CH-3785431